First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: A phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity Academic Article uri icon

Overview

MeSH Major

  • Anticoagulants
  • Antidotes
  • Aptamers, Nucleotide
  • Factor IXa

abstract

  • These observations represent a first-in-human experience of an RNA aptamer and its complementary oligonucleotide antidote used as an anticoagulant system. The findings contribute to an emerging platform of selective, actively reversible anticoagulant drugs for use among patients with thrombotic disorders of the venous and arterial circulations.

publication date

  • December 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1161/CIRCULATIONAHA.106.668434

PubMed ID

  • 17101847

Additional Document Info

start page

  • 2490

end page

  • 7

volume

  • 114

number

  • 23